REG - Ergomed plc - Issue of shares and PDMR

ErgomedAnnouncement

26/04/2018 10:00

2018-04-26T08:58:58.193Zreuters.comtag:reuters.com,2018-04-26:newsml_RSZ2237Ma:13TXT
This file is provided for EAP sample purposes only; it's structure and detail are subject to change, and should not be used as a definitive reference for actual development and processing.2018-04-26T08:58:58.193Z2018-04-26T08:58:58.193Z____UCDP:parsn_lse_10.54.4.69_1.2.37102:2019-05-26T08:58:58.193Z3RSZ2237MaREG - Ergomed plc  - Issue of shares and PDMRHealthcare (TRBC level 1)Pharmaceuticals & Medical Research (TRBC level 2)Biotechnology & Medical Research (TRBC level 4)Bio Therapeutic Drugs (TRBC level 5)Western EuropeUnited KingdomEuropeSuggested SourcesNews AnnouncementsRegulatory Corporate News AnnouncementsCompany NewsEurope daily earnings hits & missesErgomed PLC








RNS Number : 2237M
Ergomed plc
26 April 2018
 

PRESS RELEASE
   FOR IMMEDIATE RELEASE
26 APRIL 2018
 
 
Ergomed Issues Second Earn-Out Shares to Former Shareholders of PharmInvent and PDMR Dealing
 
London, UK - 26 April 2018: Ergomed plc (LSE: ERGO) ('Ergomed') or the 'Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry, today announces that the conditions for the issue of 100,818 additional new ordinary shares of 1p each in the Company to former shareholders of European Pharminvent Services s.r.o. ("Pharminvent") have been satisfied ("Second Earn-Out Shares").
 
Ergomed has approved the allotment and issue of the Second Earn-Out Shares as part of the contingent consideration for the acquisition of Pharminvent, announced on 29 November 2016. Under the terms of this deal, Ergomed acquired 100 per cent of the issued share capital of Pharminvent for an initial consideration of €4.8 million (£4.1 million), with contingent consideration based on the achievement of EBITDA targets for 2016, 2017 and 2018 of up to an aggregate further €3.2 million (£2.7 million). The initial and contingent consideration (earn-out) are both satisfied 80% in cash and 20% in new Ergomed ordinary shares.
 
In connection with the Second Earn-Out Shares, Dr Jan Petracek, Chief Operating Officer of the Company, will receive 50,409 new ordinary shares at a price of 187.25 pence per share. Following the issue of the Second Earn-Out Shares, Jan Petracek will hold 418,006 ordinary shares in the Company (representing 0.93 per cent. of the Company's issued share capital).
 
An application has been made for the admission to trading on AIM of the Second Earn Out Shares ("Admission"). Admission is expected to take place on 1 May 2018. The Second Earn Out Shares will rank pari passu in all respects with Ergomed's existing shares in issue. Following Admission, the Company's enlarged issue share capital will comprise 44,811,602 Ordinary Shares with one voting right per share. No shares are held in Treasury. The total number of voting rights in the Company is therefore 44,811,602. The figure of 44,811,602 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
 
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
 
Ends
 




1


Details of the person discharging managerial responsibilities/person closely associated




a)


Name


Dr Jan Petracek




2


Reason for the notification




a)


Position/status


Chief Operating Officer




b)


Initial notification /Amendment


Initial Notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Ergomed Plc




b)


Legal Entity Identifier


213800BVS8I9VMC1AP84




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument
 
Identification code


Ordinary shares of 1 pence each
 
 
 GB00BN7ZCY67




b)


Nature of the transaction


Acquisition of shares




c)


Currency


GBP




d)


Price(s) and volume(s)


Price(s)


Volume(s)




187.25p


50,409














e)


Aggregated information
- Aggregated volume
- Price
- Aggregated total


Volume: 50,409
Price: 187.25p
Aggregated volume: £94,390.85




f)


Date of the transaction


Admission of the shares expected on 1 May 2018




g)


Place of the transaction


London Stock Exchange, AIM




 
 
Enquiries:
 




Ergomed plc


   Tel: +44 (0) 1483 503205




Stephen Stamp (Chief Executive Officer)


















Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Michael Meade / Freddie Barnfield (Nominated Adviser)








James Black (Joint Broker)


















N+1 Singer


Tel: +44 (0) 20 7496 3000




Alex Price (Joint Broker)


















 
 
 
Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Mary-Jane Elliott
Ivar Milligan / Philippa Gardner


















MC Services - for Continental European enquiries


Tel: +49 211 5292 5222




Anne Hennecke













 
 
About Ergomed
 
Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed's fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCVQLBLVZFEBBD